Vaccines

Advancing immunization science worldwide

Vaccine Development Excellence

SXR Laboratories conducts comprehensive vaccine trials from early immunogenicity studies through large-scale efficacy trials. We have experience with traditional and novel vaccine platforms.

Our Capabilities

mRNA vaccine trials
Viral vector vaccines
Protein subunit vaccines
Pediatric immunization studies
Booster and combination vaccines
Immunogenicity assessments

Foundational Technologies & Platforms

Next-Generation Vaccine Technologies

mRNA Vaccines: Revolutionary platform using messenger RNA to instruct cells to produce harmless pieces of pathogens (e.g., SARS-CoV-2 spike protein), triggering robust immune responses. Enables rapid development and manufacturing.

Viral Vector Vaccines: Using harmless viruses (typically chimpanzee adenovirus or modified vaccinia) as vehicles to deliver genetic code for pathogen antigens, providing strong cellular and humoral immunity.

Self-Amplifying RNA (saRNA): Advanced mRNA technology enabling lower doses through RNA self-replication within cells.

Traditional Vaccine Platforms

Subunit/Recombinant Vaccines: Using purified protein components of pathogens (e.g., Hepatitis B surface antigen, HPV L1 protein) produced in cell cultures for targeted immunity.

Conjugate Vaccines: Linking weak polysaccharide antigens to strong protein carriers to boost immune response, particularly effective for bacterial infections (pneumococcal, meningococcal).

Inactivated/Attenuated Vaccines: Traditional whole pathogen approaches using killed or weakened organisms.

Immune Enhancement Technologies

Adjuvants: Immune-boosting compounds (aluminum salts, AS01, CpG oligonucleotides) added to vaccines to enhance and prolong immune responses, particularly important for subunit vaccines. Novel Delivery Systems: Lipid nanoparticles (LNPs) for mRNA vaccines, and virus-like particles (VLPs) mimicking viral structure without genetic material. Targeted Antigen Design: Computational design of stabilized antigens and epitope-focused immunogens for improved efficacy.

Global Reach

Our global network enables rapid enrollment for large-scale vaccine trials across diverse populations, with expertise in cold chain management and mass vaccination protocols.

Integrated Research Excellence

Vaccine development leverages our global research infrastructure and expertise. Clinical Trials Management orchestrates large-scale, multi-country immunization studies with cold chain logistics and mass vaccination protocols. Regulatory Affairs coordinates global vaccine submissions and liaisons with health authorities for emergency use authorizations. Biostatistics designs immunogenicity and efficacy studies with appropriate population-level endpoints. Data Management manages complex immunological data and safety surveillance across diverse populations. Quality Assurance monitors vaccine storage and administration protocols, while Medical Writing prepares comprehensive vaccine dossiers for regulatory authorities worldwide.